EU First To Approve Novartis’s Cholesterol Drug Leqvio
Twice Yearly Dosing Is Key Selling Point
Executive Summary
Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.